Roche to Acquire 89bio in $3.5B Deal to Advance Liver and Metabolic Therapies

San Francisco, CA, September 17, 2025 (Globe Newswire) -- Roche announced an agreement to acquire 89bio, a clinical-stage biotech developing therapies for liver and cardiometabolic diseases, in a transaction valued at up to $3.5 billion. Under the terms, shareholders will receive $14.50 per share in cash at closing plus a contingent value right of up to $6.00 per share tied to specific milestones. The acquisition brings Roche the late-stage candidate pegozafermin, positioned as a potential best-in-class treatment for moderate to severe metabolic dysfunction-associated steatohepatitis (MASH), and will integrate 89bio into Roche’s Pharmaceuticals Division.

Read full article here.